



## Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,  
315-321 Lockhart Road,  
Wan Chai, Hong Kong, China

### ESPS Peer-review Report

**Name of Journal:** World Journal of Methodology

**ESPS Manuscript NO:** 5388

**Title:** Overview on translational (radio)pharmaceutical research related to certain oncological and non-oncological applications

**Reviewer code:** 00057868

**Science editor:** Song, Xiu-Xia

**Date sent for review:** 2013-09-05 09:03

**Date reviewed:** 2013-09-23 08:07

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)		BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

### COMMENTS TO AUTHORS

There is much information in this article, however the review contains no new information and would be better suited in a textbook on targeted radiopharmaceutics. While the references to translational medicine are important, much of this work has been a part of the clinical arena for many years and so publication in the World Journal of Methodology would only be for historical purposes.



## Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,  
315-321 Lockhart Road,  
Wan Chai, Hong Kong, China

### ESPS Peer-review Report

**Name of Journal:** World Journal of Methodology

**ESPS Manuscript NO:** 5388

**Title:** Overview on translational (radio)pharmaceutical research related to certain oncological and non-oncological applications

**Reviewer code:** 00291404

**Science editor:** Song, Xiu-Xia

**Date sent for review:** 2013-09-05 09:03

**Date reviewed:** 2013-09-25 00:44

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

### COMMENTS TO AUTHORS

In this review article, the authors have provided a very good overview of translational research of radiopharmaceuticals for theragnostic purposes. One major focus is about OncoCiDia, a generic and unconventional theragnostic approach for solid cancers. This is a well-written manuscript. It provides rationales and detailed methodology for application of radiopharmaceutical strategies for diagnosis and treatments of solid cancer and other diseases. This paper will be useful to both experts and newcomers. There are a few minor typo errors. For example, 1. Page 9, line 10 from the bottom. "ncreasingly" should be "increasingly". 2. Page 31, ref#7. The journal name should be "Eur J Nucl Med Mol I" ("I" was missing) These corrections can be done at the proof st